Navigation Links
Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
Date:7/12/2012

SAN DIEGO, July 12, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly created position, Mr. Morris will oversee the statistical design of the company's human clinical trials.

"Mark provides an enormous amount of technical expertise in statistical design and analysis," said Steven J. Mento, Ph.D., President and CEO. "His broad experience in drug development including the hepatology field will be particularly important as we move forward with the development of emricasan, our caspase inhibitor, targeted as a treatment for a variety of fibrotic diseases."

During the past few months, Mr. Morris has been a consulting statistician to the pharmaceutical industry.  Prior to that, he had a lengthy career at Pfizer Ltd. Global Research and Development in Sandwich, Kent, England.  Mr. Morris held various positions of increasing responsibility at Pfizer, most recently as Director, Pulmonary Vascular Disease where he led a team of statisticians supporting a U.S. regulatory marketing submission.  Earlier, and of key importance, was the involvement of Mr. Morris as a Director within the GI/Hepatology Therapeutic Area and as lead statistician in the development of emricasan at Pfizer.

In Mr. Morris' role as Director of GI/Hepatology, he was a key contributor in the regulatory strategy for clinical trial design in the areas of liver fibrosis and NASH (non-alcoholic steatohepatitis).  He also worked closely with U.S., U.K. and European regulatory agencies, external medical communities and academic institutions.

"I welcome the opportunity to continue the development of emricasan as it advances into Phase 3 clinical trials.  Emricasan has the potential to significantly impact diseases that are caused by chronic inflammation, fibrosis and organ destruction.  My history with this drug candidate will provide an unusual
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
3. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
4. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
5. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
6. NJIT author to discuss newest book at Morris Museum on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... new study of satellite data from the last 19 years ... sea-level around the coast of Antarctica to rise by 2cm ... the University of Southampton detected the rapid rise in sea-level ... than a million square kilometres. , The melting ... ice shelves has contributed an excess of around 350 gigatonnes ...
(Date:8/31/2014)... CAMBRIDGE, MA -- Over the past several decades, malaria diagnosis ... a patient, a technician smears the blood across a glass ... a microscope for the Plasmodium parasite, which causes the disease. ... are in the blood an important measure of disease ... for human error. , A research team from the Singapore-MIT ...
(Date:8/29/2014)... UC Davis have made some surprising discoveries about ... simian immunodeficiency virus (SIV), the team found that ... are early responders to viral invasion and are ... cytokine called interleukin-1 beta (IL-1β). , Though ... breakdown of the gut epithelium that provides a ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2
... eastern Pacific populations of leatherback turtles, the 21st century ... change could exacerbate existing threats and nearly wipe out ... nests buried at hotter, drier beaches are the leading ... a new study in the journal Nature Climate ...
... 2012 Scientists at The Scripps Research Institute have discovered ... within cells. The scientists highlighted the medical potential of the ... to an experimental gene therapy against HIV infection. "We ... the troubles that have long been linked to traditional gene ...
... highly valued, highly cited research and reviews to the ... report that the new impact factors align with community ... the highest impact research and reviews in the biomedical ... by Thomas Reuters. Cell Press,s flagship journal ...
Cached Biology News:Rising heat at the beach threatens largest sea turtles, climate change models show 2Rising heat at the beach threatens largest sea turtles, climate change models show 3Scripps Research Institute Scientists Develop Alternative to Gene Therapy 2Scripps Research Institute Scientists Develop Alternative to Gene Therapy 3Scripps Research Institute Scientists Develop Alternative to Gene Therapy 4Cell Press journals continue to deliver high impact 2Cell Press journals continue to deliver high impact 3
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... product to poultry, red meat and pork processing ... ... 19 Tasker Products Corp.,(OTC Bulletin Board: TKER), a distributor and ... has received authorization from the Food Safety and Inspection,Service ("FSIS") of ...
... Biotechnologies,announced today the results of an on-going Phase I/II ... ASCO meeting, 2008).,Continuing on with the planned dose-escalations of ... in a Phase I safety study (Molecular,Therapy, 2008), the ... i.v. two to three times a week for 4,weeks, ...
... Lack of Global Statistics Prompts Creation of First Global,Resource ... Alliance, a newly formed Non-Governmental,Organisation, today called on governments ... prevention, diagnosis and treatment for people living,with chronic viral ... that 500 million, approximately one in 12,people, are infected ...
Cached Biology Technology:Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 3ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 2World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic 3
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Mycoplasma and virus tested...
... MagicMark XP Western Protein Standards are ... protein molecular weight estimation directly on ... an IgG binding site, allowing direct ... used to detect your target protein ...
... Clone/PAD: 3F10B10. Immunogen: Synthetic ... region of JAB1 (Jun activation ... Specificity: Specific for the JAB1 ... controls: 293T Jurkat cell lysates). ...
Biology Products: